News Center

Home page

Peak Report

News reports

Jianfeng Group Lin2017 -002 (Announcement of Resolutions of the 10th Session of the 9th Board of Directors of Jianfeng Group)

Release time:

2020-08-05

Securities Abbreviations: Jianfeng Group Securities Code: 600668 No.: Pro 2017-002

Bond Abbreviations: 13 Peak 01 Bond Code: 122227

Bond Abbreviations: 13 Peak 02 Bond Code: 122344

Zhejiang Jianfeng Group Co., Ltd.

Announcement of the Tenth Session of the Ninth Board of Directors

The board of directors and all directors of the company guarantee that the content of this announcement does not contain any False records, misleading statements or major omissions, and bear individual and joint responsibility for the authenticity, accuracy and completeness of its contents .

1. Board Meeting

(I) The convening and convening of this board meeting complies with relevant laws, regulations and the company's "Articles of Association.

(II) 2017# On February 23, 36, the company issued the notice of the board meeting by fax, e-mail and personal service.

(III) 2017# On February 28, 40, the board meeting was held by means of communication voting.

The (IV) company currently has eight directors and eight directors participating in the voting.

Review of 2. Board Meeting

, Proposal on Foreign Investment of Subsidiaries

After deliberation and voting, the Board of Directors passed the Proposal on Foreign Investment of Subsidiaries.

Voting result: 8

votes in favor, 0 votes against, 0 abstentions.

For details, please refer to the "Announcement on Foreign Investment of Subsidiaries" (Pro 2017-003

)

Independent directors of the company expressed independent opinions on the investment matter, and believed that:(1)

The voting procedure of the "Proposal on Foreign Investment of Subsidiaries" complies with relevant laws, regulations and the company's "Articles of Association", and the decision-making procedure is legal and effective. The transaction follows the principles of fairness, openness and impartiality, and the pricing is fair and reasonable, and there is no harm to the interests of the company and shareholders. (2) The parties to the transaction jointly commissioned Beijing North Asia Asset Appraisal Firm, which is qualified to practice securities, to evaluate the subject matter of the investment and issued the Appraisal Report (North Asia Appraisal Zi [2016] No. 01-610). It is considered that the selection procedure of the asset appraisal institution is legal, the ability of the appraisal institution to meet the requirements of this appraisal work, and the appraisal process is independent. (3) The relevant information on the above-mentioned foreign investment matters is complete, and the company's management has effectively communicated with us. We believe that the foreign investment is in line with the company's development strategy, which is conducive to expanding the scale of the company's pharmaceutical industry, enhancing the company's sustainable development ability and competitiveness, and ensuring the healthy and stable development of the enterprise. (4) We agree that the Company will sign an agreement with the counterparty on this foreign investment.

, Proposal

on Authorization to Chairman of the Board of Directors Since Jianfeng Pharmaceutical's foreign investment will be carried out in four phases with a long time span, the latter phases of investment are closely related to many factors such as product development progress and the operation of the target company, especially the investment prices of the third and fourth phases will be determined through negotiation based on the evaluation results at that time.

In order to ensure the implementation of the investment, the board of directors is requested to authorize the chairman to organize the implementation of the investment and fully handle all matters related to the investment. The specific content includes but is not limited to: representing the company for the implementation of the investment project (Including Jianfeng Pharmaceutical) Sign contracts, agreements and other related documents, and decide whether to make later investment when the abnormal situation stipulated in the "Agreement" occurs; determine the investment price for the third and fourth phases; and determine other matters agreed in the Agreement that require the Company to make decisions at a later stage.

After deliberation and voting, the board of directors passed the "Proposal on Authorization of the Chairman".

Voting result: 8

votes in favor, 0 votes against and 0 abstentions.

is hereby announced.

Zhejiang Jianfeng Group Co., Ltd.

Board of Directors

February 28, 2017

More information

The company fully deploys 2018 work

On January 27, the group company held a business analysis meeting to review and summarize the work in 2017, arrange and deploy the work for the new year, and put forward work requirements. At the meeting, various professional companies and directly affiliated enterprises reported on the overall work situation in 2017, focusing on analyzing the existing problems and deficiencies, and proposing corresponding solutions and work plans for 2018. Xiang Chongping, deputy general manager of the group company, systematically combed the current human resources efficiency and human resources development of the company. Chen Tianci, chairman of the board of supervisors, made a report and analysis on the "three reductions and three improvements" and the safety and environmental protection work in 2017. Lan Xiaolong, head of finance, analyzed the risks and challenges currently faced by the company according to the operating data and financial situation of its subordinate enterprises. The functional departments and offices of the headquarters also made a brief report on their annual work. Yu Jianhong, general manager of the group company, made a comprehensive review of the company's operation in 2017, compared and analyzed the main economic indicators of various industrial sectors, and pointed out that looking for new investment and development projects around strategic objectives, promoting the optimization of organizational structure and post setting, significantly improving the level of information management, improving the ability of fund management and tax planning, achieving certain results in scientific and technological innovation and technological transformation, and strengthening marketing management and market expansion, safety and environmental protection work is basically up to standard, training and talent development have achieved new results and other work highlights; at the same time, it summarizes and reflects on the shortcomings in strategic decision-making, management innovation, performance appraisal, market operation, and talent team building. After analyzing the current macroeconomic situation and the future trends of various related industries, Yu Jianhong informed

2020

07-31

Peak Pharmaceutical Invests in Shanghai North Carolina to Build API R & D and Production Base

News from our newspaper On January 19, the group company held the second meeting of the tenth board of directors and reviewed and approved the "Proposal on Foreign Investment of Subsidiary Jianfeng Pharmaceutical." On the same day, Jianfeng Pharmaceutical signed an agreement to invest in Shanghai North Carolina Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Shanghai North Carolina") by acquiring shares and increasing capital. Shanghai Beika is a high-tech enterprise in Shanghai. It has an academician expert workstation and a number of Shanghai high-tech achievements transformation projects. It has won the title of "second prize for scientific and technological progress" in Songjiang District, Shanghai, "patent pilot enterprise" and "enterprise technology center" in Songjiang District, Shanghai. The company has strong research and development capabilities and has obtained 14 patents. At present, its main business is to provide products and customized services for domestic and foreign pharmaceutical companies. The products mainly include Tinib, alkaloids, carbohydrates and other anti-tumor drug intermediates. The customized services are mainly CDMO (contract development and manufacturing) of new drugs and intermediates. Shanghai North Carolina has two wholly-owned subsidiaries, Anhui Changtai Chemical Co., Ltd. (hereinafter referred to as "Changtai Chemical") and Anhui North Carolina Pharmaceutical Co., Ltd. (hereinafter referred to as "Anhui North Carolina"). Changtai Chemical is a pesticide manufacturer designated by the Ministry of Industry and Information Technology. It was established in July 2007. It now has three chemical synthesis workshops and a pesticide preparation compounding workshop, with 10 product approvals and 13 patents. Anhui North Carolina was established in December 2016. Its business scope includes the customization, production and sales of chemical raw materials and pharmaceutical intermediates, and the wholesale and retail of chemical raw materials and products (except hazardous chemicals

2020

07-30

Peak Pharmaceutical Invests in Shanghai North Carolina to Build API R & D and Production Base

2020

07-31

Jianfeng Pharmaceutical was rated as a provincial trademark brand demonstration enterprise

On December 28, 2017, Zhejiang Administration for Industry and Commerce announced the list of trademark brand demonstration counties (cities, districts), demonstration towns (streets) and demonstration enterprises in Zhejiang Province in 2017. Jianfeng Pharmaceutical Company was identified as a trademark brand demonstration enterprise, and it was also the only enterprise in Jinhua City to enter the list. Peak Pharmaceutical was established in 1998 and obtained the first registered trademark in 1999. Since then, Jianfeng Pharmaceutical has been actively carrying out brand building in accordance with the requirements of the Trademark Law and other laws and regulations, and has set up an intellectual property department to carry out trademark management, rights protection and other activities; it has established a sound trademark management system, strictly in accordance with the provisions of the Trademark Law to supervise and manage the use of trademarks inside and outside the enterprise, and safeguard the legitimate rights and interests of the enterprise. Establish strategic cooperation with professional institutions, for trademark applications, renewals and other work. In recent years, Jianfeng Pharmaceutical has also explored trademark investment, creating value through intangible assets such as trademarks and brands, promoting efficiency improvement, and further expanding corporate influence; at the same time, it has continuously increased investment in new product research and development and technological transformation, and actively Declare various patents to provide strong support for brand building with technological innovation. According to incomplete statistics, Jianfeng Pharmaceutical and its subsidiaries currently have more than 120 valid trademarks, including 1 well-known trademark in China, 2 well-known trademarks in Zhejiang Province, 5 well-known trademarks in Jinhua City, and 2 overseas registered trademarks; Obtained more than 40 domestic and international patents. Trademark is an important part of intellectual property rights, in the knowledge economy, brand effect is increasingly becoming the leading force of economic development.

2020

07-31

Peak Pharmaceutical Invests in Shanghai North Carolina to Build API R & D and Production Base

2020

07-31

The company was rated as an advanced unit of the city's focus on talent and love talent.

News from our newspaper On December 11, the Talent Work Leading Group of the Jinhua Municipal Committee of the Communist Party of China commended the advanced units of Jinhua City that value talents and love talents. 36 units including Jianfeng Group won this honor. The selection of advanced units that value talents and love talents is a measure taken by the Jinhua Municipal Party Committee to further create a good atmosphere of focusing on talents and loving talents, fully respect and make good use of the first resource of talents, serve innovation to drive development, and implement the development strategy of strengthening the province with talents and innovation. The enterprises and institutions that have won this honorary title have always regarded talents as the fundamental driving force for development for a long time, regarded the investment of talents as the most effective investment, and integrated the love of talents into the unit culture. Remarkable achievements have been made in gathering talents, achieving talents, transforming and upgrading, and accelerating development. The Jinhua Municipal Party Committee requires the majority of employers to learn from advanced units, vigorously promote the trend of focusing on talents and loving talents, remove the obstacles to the talent development system and mechanism, and in accordance with the requirements of "walking in the forefront and jointly building Jinhua", in order to promote the construction of a modern metropolitan area and accelerate the construction of the province An important growth pole for high-quality development provides talent support and intellectual guarantee. (this newspaper reporter)

2020

07-31

< 1...38 39 40...61 > 跳转到页